Bicara Therapeutics INC

Bicara Therapeutics announces the appointment of Jeremy Bender, Ph.D., and Christy Oliger to its Board of Directors, enhancing its strategic and commercial expertise.

Bicara Therapeutics reported that its lead drug candidate doubled the three-year survival rate for head and neck cancer patients compared to current standard treatments.

Bicara Therapeutics reported Q1 2026 financial results, highlighted progress in its pivotal FORTIFI-HN01 trial for ficerafusp alfa, and announced key executive appointments.

Bicara Therapeutics initiated Phase 3 of its pivotal FORTIFI-HN01 trial, strengthened liquidity with a $161.8M offering, and guided to an interim readout in mid-2027 while reporting higher FY25 R&D spend and net loss.

Bicara Therapeutics Inc. successfully closed a public offering of common stock and pre-funded warrants, raising approximately $161.8 million in net proceeds to advance its lead oncology candidate, ficerafusp alfa.

Bicara Therapeutics announced positive Phase 1b data for ficerafusp alfa in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, supporting a less frequent dosing regimen.

Bicara Therapeutics Inc. reported a net loss of $56.2 million for the first quarter of 2026, with a significant increase in research and development expenses driven by clinical trial activities.

Bicara Therapeutics reported a significant increase in net losses and cash burn for Q3 2025, while highlighting positive Phase 1/1b clinical trial data for its lead candidate, ficerafusp alfa.

Bicara Therapeutics reported a significant increase in net loss for Q2 2025, driven by higher research and development expenses as its lead oncology program advances, while maintaining a strong cash position into 2029.

Bicara Therapeutics reports a net loss of $36.8 million for Q1 2025, with significant increases in research and development expenses due to ongoing clinical trials.

Bicara Therapeutics reports a net loss of $17.48 million for the third quarter of 2024, following a successful IPO that raised $332.4 million.

Bicara Therapeutics' 2024 10-K filing highlights the company's ongoing clinical development of ficerafusp alfa, its lead bifunctional antibody, and its financial position.

Jeremy Bender, a Director of Bicara Therapeutics Inc., received 38,950 shares of common stock on July 28, 2026.

Christy J. Oliger, a Director of Bicara Therapeutics Inc., received 38,950 shares of common stock on July 28, 2026.

Claire Mazumdar, Chief Executive Officer and a Director of Bicara Therapeutics Inc., sold 10,000 shares of common stock on July 10, 2026.

Bicara Therapeutics Inc. reports that Ryan Cohlhepp, President and COO, sold a significant number of common shares and exercised stock options as part of a pre-arranged trading plan.

Bicara Therapeutics Inc. Chief Financial Officer, Ivan Hyep, reported transactions involving the sale of company stock and the acquisition of stock options on July 8, 2026.

RA Capital Management, L.P. and its affiliates report the grant of a stock option to Jake Simson, a director and partner at RA Capital Management, for 19,475 shares of common stock.

Bicara Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 9, 2026, to elect directors and ratify auditor appointment.

Bicara Therapeutics has scheduled its annual stockholder meeting for June 9, 2025, featuring proposals for director elections and auditor ratification.

Bicara Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 9, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Bicara Therapeutics has filed a registration statement to increase the number of shares available for its public offering by 3,213,236, including an underwriter option.

Bicara Therapeutics is seeking to raise $228.4 million through an IPO to fund the clinical development of its lead drug candidate, ficerafusp alfa, and expand its research into other solid tumors.

Bicara Therapeutics updates its bylaws, detailing stockholder meeting procedures and director responsibilities, as it prepares for its initial public offering.

Bicara Therapeutics advances its IPO plans with an amended S-1 filing, detailing its bifunctional antibody therapy and upcoming clinical trials.

Bicara Therapeutics updates its investor rights agreement, outlining registration rights, information access, and other key provisions for major investors as it prepares for a possible public offering.

RA Capital Management and its affiliates increased their beneficial ownership in Bicara Therapeutics Inc. to 11.5% following a $40 million investment in a public offering.

Vestal Point Capital, LP and Ryan Wilder have disclosed a beneficial ownership of 8.3% in Bicara Therapeutics Inc., holding 5,425,000 shares of common stock.

Janus Henderson Group plc has reported beneficial ownership of 5.1% of Bicara Therapeutics Inc.'s common stock, indicating a significant investment position.

Deep Track Capital, LP, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported beneficial ownership of 6.21% of Bicara Therapeutics Inc.'s common stock as of March 31, 2026.

Red Tree Venture Fund and associated entities have reduced their ownership in Bicara Therapeutics to 4.8%, falling below the 5% reporting threshold.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 3.2% of Bicara Therapeutics Inc.'s common stock as of March 31, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.1% of Bicara Therapeutics Inc.'s common stock as of March 31, 2026.